1 / 22

STRUCTURE AND PROCESS OF PERIODIC SAFETY UPDATE REPORTING SYSTEM MEDICINES IN KENYA

STRUCTURE AND PROCESS OF PERIODIC SAFETY UPDATE REPORTING SYSTEM MEDICINES IN KENYA. KIOGORA MWITI GATIMBU REG NO.U51/64042/2013 M.PHARM-EPIVIGIL 24 TH NOVEMBER, 2014. Outline. Introduction Rationale Objectives Methodology Results Conclusion Acknowledgements. Introduction.

lottiec
Download Presentation

STRUCTURE AND PROCESS OF PERIODIC SAFETY UPDATE REPORTING SYSTEM MEDICINES IN KENYA

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. STRUCTURE AND PROCESS OF PERIODIC SAFETY UPDATE REPORTING SYSTEM MEDICINES IN KENYA KIOGORA MWITI GATIMBU REG NO.U51/64042/2013 M.PHARM-EPIVIGIL 24TH NOVEMBER, 2014

  2. Outline • Introduction • Rationale • Objectives • Methodology • Results • Conclusion • Acknowledgements

  3. Introduction • Periodic safety update report(PSUR) is a document that Marketing Authorization Holders(MAHs) submit to regulatory authority to evaluate medicinal products safety data for a particular interval of time. • PSURs owe its origin to the Council of International Organization of Medical sciences(CIOMS) guideline of 1992.

  4. Introduction • This guideline became widely accepted in all International Conference for Harmonization(ICH) regions. • ICH brings together regulatory authorities of Europe, Japan and USA to discuss scientific and technical aspect of product registration. • PSUR aim is to provide an update of world wide safety experience of specific medicinal products.

  5. Rationale for study of PSURs • ADRs are a public health concern - Aim to protect health of population. • For early detection of ADRs pharmacovigilance (PV)is of essence. • PSURS form part of tools used in PV reporting. • The study aimed at analyzing the content, process and structure of PSURs to find out whether they are able to collect relevant information for regulatory action.

  6. Objectives Broad objective To assess the structure, content and process of periodic safety update reports in Kenya Specific objectives • To examine the content of PSURs in Kenya. • To explore the organizational structure of PSURs in Kenya. • To examine the processes of PSURs in Kenya.

  7. Methodology • A cross-sectional qualitative study of documentary material. • Scotts adapted version of Leavitt’s Diamond model.

  8. Methodology • Descriptive interviews with key informants at PPB,Kenya. • A universal sampling was done.

  9. Methodology • Data was abstracted from the PSURs by use of a PSUR review tool and key informant interview tool. • Descriptive and univariate analysis was done on all the variables. • The data was analyzed using stata version 10.0

  10. Results

  11. Submitted documents marked as PSURs • All documents labeled as PSURs dated between January, 2013 to January, 2014 were eligible for inclusion in the study. • A total 120 documents were identified for review. • However, 31 documents were excluded because of being in a poor physical condition. • A further 57 documents were excluded because, though they had been filed as PSURs, they did meet the minimum criteria for PSURs

  12. Exposure number calculation method

  13. Studies and other information

  14. Overall safety components

  15. Process of PSUR reporting • Marketing authorization holders(MAHs),submit 2 hard copies. • A soft copy • A cover letter is signed and a copy is retained at the department. • They are coded and entered in an excel sheet awaiting assessment and review.

  16. Conclusion • PPB had a well laid structure for PSUR reporting. • Lacked harmonized format for capturing information. • Non mandatory requirement by the regulatory authority to submit PSURs. • No regular PSURs reviews.

  17. Conclusions • Nearly half of reviewed PSURs reported drug interactions. • 50% of PSURs reviewed had potential safety concerns. • Nearly two-thirds reported medication errors and medicine abuse and misuse. • Local MAHs do not submit PSURs

  18. Recommendations • Urgent need for policies on PSURs. • PV team to develop and implement structured PSURs review tools. • The board to employ adequate staff to facilitate regular PSURs reviews for timely detection of signals. • The regulatory authority to develop comprehensive guidelines and SOPs on PSURs.

  19. Recommendations • Local MAHs to submit PSURs to the regulatory authority. • To set aside funds to facilitate regular reviews.

  20. Acknowledgements • I wish to acknowledge the contribution and guidance of my supervisors; • Dr George Osanjo • Dr James Riungu • Dr Wesley Ronoh • My course coordinator Dr Faith Okalebo • Pharmacovigilance team at the PPB.

  21. THANK YOU

More Related